Continue reading below for a variety of comments from competitors and collaborators of Astex Pharma ASTX from 3q-2012 earnings conference calls
See comments below from Celgene $CELG 2q-2012 conference call (transcript via SeekingAlpha) related to VIDAZA, the key competitor to DACOGEN, Astex Pharma's myelodysplastic syndome (MDS) drug licensed to Eisai and Johnson & Johnson $JNJ. Note that both ASTX and Celgene are also developing "next-generation" verisions of their drug. See more about SGI-110 here.
"Compared to the second quarter of 2011, the significant increase in gross margin is partly due to a decrease in VIDAZA royalties after the product's loss of exclusivity in the U.S. in May of 2011."
"Second quarter VIDAZA sales were a record $201 million. Sequential quarterly sales grew 8% with strong year-on-year growth of 24%. In the U.S., sequential quarterly sales increased by 12% to $82 million and 12% year-on-year. Second quarter international VIDAZA sales grew to $119 million, up 6% quarter-on-quarter and 25% year-on-year. We expect new markets and increasing market share, plus duration of treatment in those existing markets, to drive improved international VIDAZA sales."
"We continually work to optimize and leverage our global MDS franchise. Our Phase III registration study for VIDAZA in acute myeloid leukemia is advancing and should serve to expand its approved indication to include all categories of patients with AML. Investigator interest to conduct research with CC-486, or oral azacitidine, is very high with 2 specific strategies under active consideration. The first seeks to develop CC-486 for a subset of low-risk MDS, and the other will test CC-486 as maintenance therapy following transplantation or other induction therapy for AML."
CELGZ Abraxis CVR
43,273,855 CVRs issued at $5.20 valuation. Cash payments up to $650m
$250m upon NSCLC approval with PFS claim ($5.77 per share)
$400m ($300m if after 4/1/2013) for approval in pancreatic cancer with OS claim ($9.24/$6.93 per share)
per calendar year ($2011 sales totaled $386m):
2.5% of sales between $1-2 B
5% of sales $2-3B
10% of sales >$3B
Final p3 NSCLC results at ASCO
-US submission 12/9/11
-EU filling targeted 1h-2012
Your support is greatly appreciated